NewslettersDermal Cell News VYNE Therapeutics Completes Enrollment in Phase IIa Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis By Bob - June 20, 2022 0 VYNE Therapeutics Inc. announced the completion of enrollment in the Phase IIa study of FMX114 for the treatment of mild-to-moderate atopic dermatitis. [VYNE Therapeutics Inc.] Press Release